MedTrace Logo

Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Cardiotrophin-1 in Healthy Volunteers

NCT01334697 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2013-07-30

No results posted yet for this study

Summary

The general aim of the study is to determinate safety, tolerability and early pharmacokinetics of cardiotrophin.1 in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

recombinant human cardiotrophin-1

Single dose intravenous administration

OTHER

Placebo

Single dose intravenous administration

Sponsors & Collaborators

  • Digna Biotech S.L.

    lead INDUSTRY

Principal Investigators

  • Belén Sádaba, MD · Clínica Universidad de Pamplona

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01334697 on ClinicalTrials.gov